Skip to content
Erudio Health
menu
Oncology · For Medical Affairs

What clinicians say about clinical trials, and why.

How oncologists read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question. Every view links to its source. Read the two-minute summary yourself, or let your AI agent work through the evidence.

Find your trialGet a free reportConnect your AI agent →

Explore the report previews

View for
Try: · · ·
Report size
TrialSizePreview
IDeate-Lung01Free
NCT05280470 · Daiichi Sankyo
DeepPreview
OrigAMI-3
NCT06750094 · Janssen Research & Development, LLC
FocusedPreview
OrigAMI-2
NCT06662786 · Janssen Research & Development, LLC
StandardPreview
MoonRISe-3
NCT06919965 · Janssen Research & Development, LLC
FocusedPreview
iMMagine-3
NCT06413498 · Kite, A Gilead Company
DeepPreview
MEVPRO-1
NCT06551324 · Pfizer
StandardPreview
KO-MEN-017
NCT07007312 · Kura Oncology, Inc.
FocusedPreview
EXCALIBER-RRMM
NCT04975997 · Celgene
DeepPreview
EAA181
NCT04566328 · ECOG-ACRIN Cancer Research Group
DeepPreview
MK-3475-975/KEYNOTE-975
NCT04210115 · Merck Sharp & Dohme LLC
StandardPreview
FURVENT
NCT05607550 · ArriVent BioPharma, Inc.
FocusedPreview
SARON
NCT02417662 · University College, London
FocusedPreview
Krascendo 1
NCT06497556 · Hoffmann-La Roche
FocusedPreview
EA3191
NCT04671667 · National Cancer Institute (NCI)
FocusedPreview
QUINTESSENTIAL-2
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
StandardPreview

15 of 15 reports

  • 15 published reports
  • any listed oncology trial built within 24 hours
  • weekly updates
  • every statement source-linked
all reports and trials →
What you get

One trial, read three ways.

Every report has the same three parts, for you, for the colleagues you forward it to, and for your AI agent.

For you and your VP

Executive summary

The two-minute read: how the clinicians who discussed the trial read it, where they differ, and the open question for Medical Affairs. A PDF to forward.

For your Medical Directors

Detailed analysis

The reasoning, disagreements, qualifications and counterviews behind each finding, to read in your browser.

For your AI agent

Structured evidence

Every verified statement with its speaker, date, short quote and link, as JSON and through the Erudio MCP, so your agent can check any finding.

Follow a trial with weekly updates: when the commentary changes a finding you get a new edition and a note of what changed, and when nothing changes you get a dated note that the report is current. See everything a report holds, including each speaker's CMS-reported financial relationships.

Free report · IDeate-Lung01

Check our work before you buy.

The open question for Medical Affairs

How should scientific exchange distinguish response activity, comparative clinical benefit and accelerated-approval sufficiency?

  1. 01Response enthusiasm and evidence sufficient for accelerated approval are different judgments
  2. 02ILD drives patient selection and monitoring, with materially different benefit–risk appraisals
  3. 03High response activity motivates interest, but durability, survival and dose trade-offs limit the inference
  4. 04CNS activity is a distinctive source of enthusiasm, with important subgroup and eligibility boundaries

The complete IDeate-Lung01 report is free: the executive summary, the analysis of every finding, and the verified statements behind them, each linked to the podcast, video or post it came from. Trace any finding to its source.

Get it freeSee the report page

347 verified statements (218 from speakers with a confirmed clinical role) from 103 commentary sources · 8 findings · updated Oct 21, 2026

What an AI agent made from it
How it compares

What you have today, and what Erudio adds.

Most teams already pay for some of these. Erudio fills the gap between them: the clinician's own reasoning about a trial, in public, with the source.

You haveIt gives youErudio adds
KOL and HCP databasesWho a clinician is: affiliations, publications, trials.What they said about a trial, where and when, with their reasoning. Use both.
Social listeningMentions and sentiment, mostly from short posts.Long-form podcasts and video as well as X, with clinical views kept apart from reactions.
Field medical insightsWhat your MSLs heard in private conversations.What clinicians say in public, with optional NPI and ORCID linkages to connect each voice to your expert records in Salesforce, Veeva or other NPI-keyed systems. It complements your field insights and never ingests them.
Agencies and congress reportsOne question per project, in weeks.A report on any listed trial within 24 hours, with every source linked, plus weekly updates.
General AI chatFast answers with uncertain sources.Every statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps.
Two products

Every report works with your agent. Enterprise adds the whole corpus.

Reports

One trial, one report, agent included

What clinicians said about a trial in podcasts, videos and posts, why their readings differ, and the source behind every view: an executive summary to forward, the analysis, and the evidence your AI agent can query, with no enterprise contract. Buy the current edition, or follow a trial with 3, 6 or 12 months of weekly updates. Trials without a report are built within 24 hours of your order.

Browse reportsPricing
Enterprise MCP

The whole corpus, for your agents

Search across all the HCP podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses, from Microsoft Copilot, ChatGPT, Claude or your own agent. Ask “prep me for my meetings with these five oncologists” and get sourced answers.

Erudio MCPRequest a pilot
Method

How a report is built

Every report separates what clinicians said from what the primary evidence establishes. We never turn commentary into an efficacy verdict or a consensus.

  1. 01

    Resolve the trial

    One registry record, its aliases, no look-alikes

  2. 02

    Gather sources

    Podcasts, videos and X posts that name the trial

  3. 03

    Screen and extract

    Each view, question and reason becomes a statement

  4. 04

    Audit

    Every statement checked against its original passage

  5. 05

    Compose

    What clinicians said and why, beside the primary facts

  6. 06

    Review

    Findings checked for fidelity and overclaiming

  7. 07

    Version and publish

    A hashed, versioned edition with a changelog

  8. Read the methods →
Use cases

Built around the jobs Medical Affairs already does.

MCP · example output

Meeting prep

Walk into a scientific exchange knowing what the clinician has already said in public.
Reports + MCP · example output

Readout reaction

See how clinicians read a trial result in the days and weeks after it lands.
Reports + MCP · example output

Congress briefing

A sourced briefing on how a congress presentation was received.
Reports · example output

Advisory boards

Build an advisory board agenda around questions clinicians actually disagree about.
Reports · example output

Competitive context

Understand how clinicians compare therapies, and where the comparison breaks down.
Reports · example output

Evidence gaps

Find the questions clinicians are asking that the evidence does not answer.
Reports + MCP · example output

Launch and access signals

Hear the practical barriers clinicians raise before and after an approval.
Reports + MCP · example output

Trial watchlist

Follow your own and competitor trials, and see only what changed.
Reports · example output

Education needs assessment

Document the practice gaps clinicians describe, with the source behind each.
Trust

Public sources only. Every statement linked. Every edition versioned, with corrections in the open.

  • Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
  • Co-founder Audun Utengen has published research with clinicians in BMJ, JAMA Oncology and the European Heart Journal
  • Erudio Health has received a Security-only SOC 2 Type II report, available under NDA
  • Reports state what they do not cover, on every page
  • Non-promotional: no efficacy verdicts, consensus scores or rankings. Trust center